Company Profile
AstraZeneca PLC Stock Price, News & Analysis
- Ticker:
- AZN
- Exchange:
- NASDAQ
- Sector:
- Small Molecule Drugs, Biologics
- Location:
- UK
Stock performance
161.07 USD (-0.27%)
Close
Last updated: August 6, 2026
275B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AZN closed down 0.27% at $161.07. No new same-company headline was identified in the current news window.
Company overview
Business overview
AstraZeneca is a global biopharmaceutical company with deep exposure to oncology, cardiovascular, renal, metabolic disease, respiratory, and rare disease. The company has become one of the market’s strongest large-cap growth stories.
Geographic Base and Sector Classification
Headquartered in the UK and listed on the U.S. as an ADR, AstraZeneca has a global operating footprint across major healthcare markets. It is a multinational biopharma with broad therapeutic reach.
Business Model Characteristics
AstraZeneca relies on blockbuster medicines, strong launch execution, and a pipeline that continues to refresh growth. Investors watch oncology momentum, pipeline readouts, and whether new launches can sustain the company’s growth profile.
Position Within the Biotechnology Landscape
AstraZeneca sits near the top of the large-cap biotech/pharma landscape because it combines scale, growth, and strong R&D execution. It is less binary than smaller biotechs but still highly reactive to major oncology and pipeline news.
Future catalysts
AstraZeneca’s watchlist should stay on camizestrant, datopotamab deruxtecan, and other late-stage oncology assets that can prove the company still has multiple shots on goal. The important part is whether the update changes the odds of the next milestone rather than just confirming the current story. If the event is positive, it can improve the market’s willingness to pay for the name ahead of the following catalyst.
Recent news
- 01
Dealing by Person Closely Associated
Source: AstraZeneca PLC
- 02
AZ completes US Aralez agreement for Toprol-XL
Source: AstraZeneca PLC
- 03
AstraZeneca Head and Neck Cancer Trials
Source: AstraZeneca PLC
- 04
Positive results in AstraZeneca Lynparza trial
Source: AstraZeneca PLC
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AstraZeneca PLC (AZN)?
AstraZeneca PLC (AZN) most recently closed at 161.07 USD, a -0.27% move versus the previous session.
What is the market cap of AstraZeneca PLC (AZN)?
AstraZeneca PLC currently has a market capitalization of 275B USD on BioPharmSignal.
What does AstraZeneca PLC do?
AstraZeneca is a global biopharmaceutical company with deep exposure to oncology, cardiovascular, renal, metabolic disease, respiratory, and rare disease. The company has become one of the market’s strongest large-cap growth stories.
On which exchange is AZN stock listed?
AstraZeneca PLC (AZN) is associated with NASDAQ, UK, Small Molecule Drugs, Biologics.
What is datopotamab?
AstraZeneca’s watchlist should stay on camizestrant, datopotamab deruxtecan, and other late-stage oncology assets that can prove the company still has multiple shots on goal.
Which conditions is AstraZeneca PLC targeting with datopotamab?
AstraZeneca PLC is associated with oncology, rare disease, cardiovascular disease based on its company overview and current catalyst commentary.
How does AstraZeneca PLC describe recent progress with datopotamab?
AstraZeneca’s watchlist should stay on camizestrant, datopotamab deruxtecan, and other late-stage oncology assets that can prove the company still has multiple shots on goal.
What is AstraZeneca?
AstraZeneca is a global biopharmaceutical company with deep exposure to oncology, cardiovascular, renal, metabolic disease, respiratory, and rare disease.